FrancophonIA/ELRC3.0 huggingface dataset:
English: − Since no data are available on the compatibility of Zoledronic Acid Hospira with other intravenously administered substances, Zoledronic Acid Hospira must not be mixed with other medicinal products/substances and should always be given through a separate infusion line.
Estonian: - Andmeid Zoledronic Acid Hospira kokkusobivuse kohta teiste veenisiseselt manustatavate ainetega on ebapiisavalt, seetõttu ei tohi Zoledronic Acid Hospira't segada teiste ravimite/ainetega ja selle manustamiseks tuleb kasutada eraldi infusioonisüsteemi.
English: The active substance in Zoledronic Acid Hospira is zoledronic acid, which belongs to a group of substances called bisphosphonates.
Estonian: Zoledronic Acid Hospira toimeaine on zoledroonhape, mis kuulub bisfosfonaatideks nimetatud ravimite rühma.
English: somnolence
Estonian: Insomnia
English: The treatment effects were less pronounced in patients with blastic lesions.
Estonian: Ravi ei olnud nii tulemuslik osteoblastsete luukahjustustega patsientidel.
English: Zoledronic Acid Hospira is contraindicated during breast-feeding (see section 4.3).
Estonian: Zoledronic Acid Hospira on vastunäidustatud imetamise ajal (vt lõik 4.3).
English: Zoledronic Acid Hospira contains sodium
Estonian: Zoledronic Acid Hospira sisaldab naatriumi
English: Zoledronic Acid Hospira (5 mg in 100 ml ready-to-infuse solution) is administered via an infusion line and given at a constant infusion rate.
Estonian: Zoledronic Acid Hospira't (5 mg 100 ml-s manustamisvalmis infusioonilahuses) manustatakse püsiva infusioonikiirusega ühe infusioonisüsteemi kaudu.
English: All patients received adequate supplementation with vitamin D and calcium in the post-menopausal osteoporosis trial, the prevention of clinical fractures after hip fracture trial, and the Paget's disease trials (see also section 4.2).
Estonian: Kõik Pageti tõve, reieluu proksimaalse osa murrule järgnevate kliiniliste murdude ennetamise ja postmenopausaalse osteoporoosi uuringutes osalenud patsiendid said piisavalt D-vitamiini ja kaltsiumi preparaate (vt ka lõik 4.2).
English: Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common ( 1/10), common ( 1/100 to <1/10), uncommon ( 1/1,000 to <1/100), rare ( 1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Estonian: Kõrvaltoimed on esitatud vastavalt esinemissagedusele, kõige sagedasemad eespool, järgmise kokkuleppe alusel: väga sage ( 1/10), sage ( 1/100 kuni < 1/10), aeg-ajalt ( 1/1000 kuni < 1/100), harv ( 1/10 000 kuni < 1/1000), väga harv (< 1/10 000), teadmata (ei saa hinnata olemasolevate andmete alusel).
English: Patients must be maintained well hydrated prior to and following administration of Zoledronic Acid Hospira.
Estonian: Patsiendid peavad enne ja pärast Zoledronic Acid Hospira manustamist olema hästi hüdreeritud.
English: Upon initiation of treatment in patients with bone metastases with mild to moderate renal impairment, lower doses of zoledronic acid are recommended.
Estonian: Kerge kuni keskmise neerukahjustusega ja luumetastaasidega patsientidele soovitatakse manustada väiksemaid zoledroonhappe annuseid.
English: Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget's disease of the bone (median serum alkaline phosphatase level 2.6-3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Estonian: Zoledroonhapet uuriti radiograafilise uuringuga kinnitatud, mõõduka kuni keskmise Pageti luutõvega (seerumi alkaalse fosfataasi keskmine tase uuringu alguses 2,6…3 korda üle ea-spetsiifilise ülemise normi piiri) nais- ja meessoost patsientidel vanuses üle 30 aasta.
English: In multiple myeloma patients, the risk of renal dysfunction may be increased when zoledronic acid is used in combination with thalidomide.
Estonian: Hulgimüeloomiga patsientidel võib samaaegne talidomiidi kasutamine koos zoledroonhappega suurendada neerufunktsiooni kahjustuse riski.
English: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodiumfree”.
Estonian: See ravimpreparaat sisaldab vähem kui 1 mmol (23 mg) naatriumi annuse kohta, see tähendab on põhimõtteliselt „naatriumivaba“.
English: CARTON FOR 1 BAG AS UNIT PACK
Estonian: 1 KOTI VÄLISKARP ÜKSIKPAKENDINA
English: - 3.8 ml for 3.0 mg dose
Estonian: - 3,8 ml kontsentraati 3,0 mg annuse valmistamiseks
English: The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 ± 33% of the creatinine clearance, which showed a mean of 84 ± 29 ml/min (range 22 to 143 ml/min) in the 64 patients studied.
Estonian: Zoledroonhappe neerukliirens korreleerus kreatiniini kliirensiga, neerukliirens oli 75 ± 33% kreatiniini kliirensist, mille keskmine väärtus 64 uuritud patsiendil oli keskmiselt 84 ± 29 ml/min (vahemikus 22 kuni 143 ml/min).
English: In patients with mild to moderate renal impairment, reduced Zoledronic Acid Hospira doses are recommended (see section “Posology” above and section 4.4).
Estonian: Kerge kuni mõõduka neerukahjustusega patsientidele on soovitatav manustada väiksemaid Zoledronic Acid Hospira annuseid (vt lõik „Annustamine“ eespool ja lõik 4.4).
English: Following initiation of therapy, serum creatinine should be measured prior to each dose of zoledronic acid and treatment should be withheld if renal function has deteriorated.
Estonian: Pärast ravi alustamist tuleb seerumi kreatiniinisisaldust määrata enne iga zoledroonhappe annuse manustamist ning kui neerukahjustus on süvenenud, tuleb ravi katkestada.
English: Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required (see section 4.4).
Estonian: Ettevaatus on soovitav bisfosfonaatide manustamisel koos aminoglükosiidide, kaltsitoniini või lingudiureetikumidega, sest nende ravimite koostoime tulemusena võib seerumi kaltsiumisisaldus langeda soovitavast rohkem ja pikemaks ajaks (vt lõik 4.4).
English: Prior to administration, 5.0 ml concentrate from one vial or the volume of the concentrate withdrawn as required must be further diluted with 100 ml of calcium-free infusion solution (sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution).
Estonian: Enne manustamist tuleb viaalis olev 5 ml kontsentraati või sellest võetud vajalik kogus lahjendada 100 ml kaltsiumit mittesisaldava infusioonilahusega (naatriumkloriidi 9 mg/ml (0,9%) süstelahusega või 5% w/v glükoosi lahusega).
English: 3.5 mg* zoledronic acid
Estonian: 3,5 mg* zoledroonhapet
English: Kidney disorders (e.g. decreased urine output) may occur.
Estonian: Esineda võib häireid neerude töös (nt vähenenud uriinieritus).
English: In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2-2.5 mg.
Estonian: I faasi uuringutes sobiva annuse leidmiseks tuumorist tingitud kerge kuni mõõduka hüperkaltseemiaga patsientidel osutus ravim efektiivseks annustevahemikus 1,2…2,5 mg.
English: Nervous system disorders Common:
Estonian: Närvisüsteemi häired Sage:
English: Single and multiple 5 and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients yielded the following pharmacokinetic data, which were found to be dose independent.
Estonian: Alljärgnevad farmakokineetilised tulemused saadi 2, 4, 8 ja 16 mg zoledroonhappe ühekordse ja korduva 5- ja 15-minutilise infusiooni manustamisel 64-le luumetastaasidega patsiendile.
English: Zoledronic Acid Hospira treatment should be resumed at the same dose as that given prior to treatment interruption.
Estonian: Ravi Zoledronic Acid Hospira'ga tuleb jätkata sama annusega, mida kasutati enne ravi katkestamist.
English: Severe and occasionally incapacitating bone, joint and/or muscle pain have been infrequently reported in patients taking bisphosphonates, including zoledronic acid (see section 4.8).
Estonian: Bisfosfonaate, sealhulgas zoledroonhapet saavatel patsientidel on harva teatatud tugevast ja mõnikord halvavast luu-, liiges- ja/või lihasvalust (vt lõik 4.8).
English: Caution is advised when Zoledronic Acid Hospira is administered with anti-angiogenic medicinal products, as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.
Estonian: Zoledronic Acid Hospira koosmanustamisel antiangiogeensete preparaatidega on soovitav rakendada ettevaatust, sest neid ravimeid samaaegselt saanud patsientidel on teatatud ONJ juhtudest.
English: - For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 µmol/l), an increase of 0.5 mg/dl or 44 µmol/l;
Estonian: - kreatiniini sisalduse tõus 0,5 mg/dl või 44 mikromol/l võrra, kui algväärtus oli normi piires (< 1,4 mg/dl või < 124 mikromol/l);
English: This medicinal product contains less than 1 mmol sodium (23 mg) per 100 ml dose of Zoledronic Acid Hospira, i.e. essentially “sodium free”.
Estonian: Ravim sisaldab vähem kui 1 mmol naatriumi (23 mg) 100 ml Zoledronic Acid Hospira annuse kohta, st on praktiliselt naatriumivaba.
English: Treatment of Paget's disease of the bone in adults.
Estonian: Pageti luutõve ravi täiskasvanutel.
English: - 4.1 ml for 3.3 mg dose
Estonian: - 4,1 ml kontsentraati 3,3 mg annuse valmistamiseks
English: The MAH shall ensure that a patient reminder card regarding osteonecrosis of the jaw is implemented.
Estonian: Müügiloa hoidja peab tagama, et patsientidel on olemas lõualuu osteonekroosi meeldetuletuskaart.
English: In clinical studies, zoledronic acid has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring.
Estonian: Kliinilistes uuringutes ei ilmnenud kliiniliselt olulisi koostoimeid zoledroonhappe kasutamisel samaaegselt teiste kasvajavastaste ravimite, diureetikumide, antibiootikumide ja valuvaigistitega.
English: It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.
Estonian: Siiani on ebaselge, kas südame rütmihäireid põhjustab zoledroonhape; kui teil aga tekivad pärast zoledroonhappe manustamist sellised sümptomid, peate te sellest oma arstile rääkima.
English: Zoledronic Acid Hospira must not be mixed or given intravenously with any other medicinal product and must be given through a separate infusion line at a constant infusion rate.
Estonian: Zoledronic Acid Hospira't ei tohi segada või manustada intravenoosselt koos mistahes teise ravimiga ning seda tuleb manustada püsiva infusioonikiirusega eraldi infusioonisüsteemi kaudu.
English: − The solution containing zoledronic acid must not be further diluted or mixed with other infusion solutions.
Estonian: - Zoledroonhapet sisaldavat lahust ei tohi edasi lahjendada ega segada ühegi teise infusioonilahusega.
English: In the pooled results, a similar decrease in pain severity and pain interference scores relative to baseline were observed over 6 months for zoledronic acid and risedronate.
Estonian: Koondandmetes täheldati nii zoledroonhappe kui ka risedronaadi kasutamisel võrreldavat valu tugevuse ja interferentsi skooride vähenemist 6 kuu jooksul võrrelduna algseisundiga.
English: To avoid potential incompatibilities, Zoledronic Acid Hospira is to be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution.
Estonian: Võimaliku sobimatuse vältimiseks tuleb Zoledronic Acid Hospira't lahjendada naatriumkloriidi 9 mg/ml (0,9%) süstelahusega või 5% w/v glükoosi lahusega.
English: Patients must be assessed prior to administration of zoledronic acid to ensure that they are adequately hydrated.
Estonian: Enne zoledroonhappe manustamist tuleb kontrollida, et patsient oleks piisavalt hüdreeritud.
English: Your doctor will carry out blood tests before you start treatment with Zoledronic Acid Hospira and will check your response to treatment at regular intervals.
Estonian: Enne Zoledronic Acid Hospira-ravi alustamist teeb arst vereanalüüsid ja kontrollib regulaarsete intervallide järel teie ravivastust.
English: The following risk factors should be considered when evaluating an individual's risk of developing ONJ: - Potency of the bisphosphonate (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bisphosphonate.
Estonian: Patsiendi individuaalse lõualuu osteonekroosi (LON) tekkeriski hindamisel tuleb arvesse võtta järgmisi riskitegureid: - bisfosfonaadi tugevus (tugevama komponendiga kaasneb suurem risk), manustamisviis
English: In patients with mild to moderate renal impairment, reduced zoledronic acid doses are recommended (see section “Posology” above and section 4.4).
Estonian: Kerge kuni mõõduka neerukahjustusega patsientidele on soovitatav manustada väiksemaid zoledroonhappe annuseid (vt lõik „Annustamine“ eespool ja lõik 4.4).
English: Caution is advised when zoledronic acid is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5).
Estonian: Ettevaatust nõuab zoledroonhappe manustamine koos teadaolevalt hüpokaleemiat põhjustavate ravimitega, sest sünergistliku toime tagajärjel võib tekkida tõsine hüpokaleemia (vt lõik 4.5).
English: ** Accounts for all skeletal events, the total number as well as time to each event during the trial
Estonian: ** Arvestades kõiki luustikuga seotud tüsistusi, nii koguarvu kui ka aega tüsistuse tekkeni uuringu jooksul
English: − The unopened vial does not require any specific storage conditions.
Estonian: - Avamata viaal ei vaja säilitamisel eritingimusi.
English: A dental examination with appropriate preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with bisphosphonates in patients with concomitant risk factors.
Estonian: Kaasuvate riskifaktoritega patsienditel on soovitatav enne ravi alustamist bifosfonaatidega teha asjakohane hammaste läbivaatus koos ennetava hambaraviga ning individuaalne kasu-riski hindamine.
English: - Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.
Estonian: - Luukude haarava kaugelearenenud pahaloomulise kasvajaga täiskasvanud patsientidel luustikuga seotud tüsistuste (patoloogilised luumurrud, seljaaju kompressioon, luude kiiritusravi või operatsioon, tuumorist indutseeritud hüperkaltseemia) ennetamine.
English: Uncommon: Dizziness, paraesthesia, dysgeusia, hypoaesthesia, hyperaesthesia, tremor, somnolence
Estonian: Pearinglus, paresteesia, düsgeusia, hüpoesteesia, hüperesteesia, treemor, unisus
English: This medicinal product must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line.
Estonian: Seda ravimit ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega ja seda peab manustama ainsa intravenoosse lahusena eraldi infusioonisüsteemi kaudu.
English: It also contains mannitol, sodium citrate, water for injections and sodium chloride.
Estonian: See sisaldab ka mannitooli, naatriumtsitraati, süstevett ja naatriumkloriid.
English: There were no statistically significant differences between the two zoledronic acid doses.
Estonian: Zoledroonhappe erinevate annuste kasutamisel ei olnud statistiliselt olulisi erinevusi.
English: Not known (frequency cannot be estimated from the available data) Pain in the mouth and/or jaw, swelling or non-healing sores in the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth, these could be signs of bone damage in the jaw (osteonecrosis).
Estonian: Teadmata (esinemissagedust ei saa hinnata olemasolevate andmete alusel) Suu ja/või lõualuu valu, turse või halvasti paranevad haavandid suuõõnes või lõuaosas, eritise teke, tuimus või raskustunne lõualuus või hamba logisemine.
English: Caution is advised when Zoledronic acid is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5).
Estonian: Ettevaatust nõuab zoledroonhappe manustamine koos teadaolevalt hüpokaltseemiat põhjustavate ravimitega, sest sünergistliku toime tagajärjel võib tekkida tõsine hüpokaltseemia (vt lõik 4.5).
English: Efficacy results are provided in Table 2.
Estonian: Efektiivsustulemuste kokkuvõte on toodud tabelis 2.
English: In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30-60 ml/min, the following zoledronic acid dose is recommended (see also section 4.4):
Estonian: Kerge kuni keskmise raskusega neerukahjustusega luumetastaasidega patsientidele kreatiniini kliirensiga 30…60 ml/min on ravi alustamiseks soovitatavad järgmised zoledroonhappe annused (vt ka lõik 4.4):
English: Zoledronic acid is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
Estonian: Zoledroonhapet ei soovitata kasutada raske neerukahjustusega patsientidel, kelle kreatiniini kliirens on < 30 ml/min.
English: Zoledronic Acid Hospira must not be mixed or given intravenously with any other medicinal products.
Estonian: Zoledronic Acid Hospira't ei tohi segada ühegi teise ravimiga ega intravenoosselt manustada.
English: − Low level of calcium in the blood.
Estonian: - Vere madal kaltsiumisisaldus.
English: Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone.
Estonian: Zoledroonhape kuulub lämmastikku sisaldavate bisfosfonaatide gruppi ja toimib otseselt luukoesse.
English: The refrigerated solution should then be equilibrated to room temperature prior to administration.
Estonian: Sel juhul tuleb jahutatud lahusel enne manustamist lasta soojeneda toatemperatuurini.
English: Concentrate for solution for infusion 4 mg/5 ml
Estonian: Infusioonilahuse kontsentraat 4 mg/5 ml
English: Zoledronic acid was teratogenic in the rat at subcutaneous doses 0.2 mg/kg.
Estonian: Zoledroonhape osutus teratogeenseks kasutatuna rottidel subkutaanselt annuses ≥ 0,2 mg/kg.
English: − The bag does not require any specific storage conditions.
Estonian: - Kott ei vaja säilitamisel eritingimusi.
English: Cardiac disorders Uncommon: Hypertension, hypotension, atrial fibrillation, hypotension leading to syncope or circulatory collapse
Estonian: Hüpertensioon, hüpotensioon, kodade virvendusarütmia, sünkoopi või vereringe seiskumist põhjustav hüpotensioon
English: 3.3 mg* zoledronic acid
Estonian: 3,3 mg* zoledroonhapet
English: It is unknown whether zoledronic acid is excreted into human milk.
Estonian: On teadmata, kas zoledroonhape eritub inimese rinnapiima.
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2
Estonian: Kui ravimit ei kasutata kohe, vastutab selle säilitamisaja ja -tingimuste eest kasutaja.
English: Dystocia was observed at the lowest dose (0.01 mg/kg body weight) tested in rats.
Estonian: Düstookiat täheldati kõige väiksema rottidel uuritud annuse kasutamisel (0,01 mg/kg/KM).
English: − Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests).
Estonian: Sage (võivad esineda kuni ühel inimesel 10-st): - Raske neerukahjustus (üldjuhul teeb arst selle spetsiaalsete vereanalüüsidega kindlaks).
English: If you experience any of the above side effects, you should contact your doctor immediately.
Estonian: Kui teil tekib ükskõik milline eespool kirjeldatud kõrvaltoimetest, rääkige sellest oma arstile.
English: Standard hypercalcaemia-related metabolic parameters, such as serum levels of calcium, phosphate and magnesium, should be carefully monitored after initiating zoledronic acid therapy.
Estonian: Pärast zoledroonhappe ravi alustamist tuleb hoolikalt jälgida hüperkaltseemiaga seotud standardseid ainevahetuse näitajaid, nagu kaltsiumi, fosfaatide ja magneesiumi sisaldus seerumis.
English: Common Influenza-like illness, chills, fatigue, asthenia, pain, malaise, infusion site reaction
Estonian: Gripisarnane haigus, külmavärinad, väsimus, asteenia, valu, halb enesetunne, infusioonikoha reaktsioon
English: Efficacy results are provided in Table 3.
Estonian: Efektiivsustulemuste kokkuvõte on toodud tabelis 3.
English: While the risk is reduced with a dose of zoledronic acid administered over 15 minutes, deterioration in renal function may still occur.
Estonian: Kuigi zoledroonhappe manustamine 15 minuti jooksul vähendab neerukahjustuse riski, ei ole see siiski välistatud.
English: Zoledronic Acid Hospira is not recommended for use in adolescents and children below the age of 18 years.
Estonian: Lapsed ja noorukid Zoledronic Acid Hospira't ei ole soovitatav kasutada alla 18-aastastel lastel ja noorukitel.
English: In the HORIZON - Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid and placebo, respectively.
Estonian: Uuringus HORIZON - Pöördelise tähtsusega luumurru uuring [Pivotal Fracture Trial (PFT)] (vt lõik 5.1) - oli keskmine kodade fibrillatsiooni esinemus zoledroonhapet ja platseebot saavatel patsientidel vastavalt 2,5% (96-l 3862-st) ja 1,9% (75-l 3852-st).
English: Skeletal morbidity rate p-value
Estonian: Ei saabunud p-väärtus Luustiku haigestumuse tase p-väärtus
English: Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with zoledronic acid.
Estonian: Zoledroonhappega ravitud patsientidel on teatatud vähenenud kaltsiumi tasemest veres (hüpokaltseemia), mis võib mõnikord põhjustada lihaskrampe, suukuivust ja põletuse tunnet.
English: * Doses have been calculated assuming target AUC of 0.66 (mg•hr/l) (CLcr = 75 ml/min).
Estonian: 3,0 mg* zoledroonhapet *annused on arvestatud lähtuvalt soovitavast AUC väärtusest 0,66 (mg•h/l) (CLcr = 75 ml/min).
English: Each pack contains one bag which contains 4 mg of zoledronic acid.
Estonian: Üks pakend sisaldab ühte kotti 4 mg zoledroonhappega.
English: Remove the following amount of Zoledronic Acid Hospira 4 mg/100 ml solution for infusion (ml)
Estonian: Eemaldage järgnev kogus Zoledronic Acid Hospira 4 mg/100 ml infusioonilahust (ml)
English: Figure 1: Mean changes from baseline in BPI scores.
Estonian: BPI skoori keskmised muutused algväärtuse suhtes.
English: - For patients with abnormal baseline creatinine (> 1.4 mg/dl or > 124 µmol/l), an increase of 1.0 mg/dl or 88 µmol/l.
Estonian: - kreatiniini sisalduse tõus 1,0 mg/dl või 88 mikromol/l võrra, kui algväärtus ei olnud normi piires (> 1,4 mg/dl või > 124 mikromol/l).
English: Proportion of patients with SREs (%)
Estonian: Patsientide arv 214 LSTdega patsiente (%) p-väärtus
English: CARTON FOR 1 VIAL AS UNIT PACK
Estonian: 1 VIAALI VÄLISKARP ÜKSIKPAKENDINA
English: Your doctor should do a blood test to check your kidney function (levels of creatinine) before each dose of Zoledronic Acid Hospira.
Estonian: Teie arst peab enne iga Zoledronic Acid Hospira annuse manustamist kontrollima vereanalüüsi abil teie neerufunktsiooni (kreatiniini tase).
English: If refrigerated, allow the refrigerated solution to reach room temperature before administration.
Estonian: Kui lahust on säilitatud külmikus, laske lahusel enne manustamist seista kuni see saavutab toatemperatuuri.
English: SN:
Estonian: Sage:
English: Zoledronic acid is not recommended in women of childbearing potential.
Estonian: Zoledroonhapet ei soovitata fertiilses eas naistele.